Reviewing Research and Development Expenditure Capitalisation Policies Before an IPO

The Hong Kong Stock Exchange (HKEX) published its 2024 annual review of listing decisions on 31 January 2025, and the data reveals a sharpening focus on accounting policy judgments that directly impact IPO eligibility. Of the 27 listing applications that received detailed comments from the Listing Division in Q4 2024, 11 involved specific queries on the capitalisation of research and development (R&D) expenditure under Hong Kong Financial Reporting Standards (HKFRS). This is not a procedural footnote. For issuers on the Main Board and GEM, the treatment of R&D costs determines whether a company meets the HK$80 million (Main Board Rule 8.05) or HK$60 million (GEM Rule 11.12A) market capitalisation/revenue tests, and more critically, whether its historical financial statements can withstand the sponsor’s due diligence and the SFC’s post-listing scrutiny. The HKEX’s 2024 Guidance Letter GL86-24 (updated in December) explicitly warns that capitalisation policies must be “consistently applied and supported by contemporaneous documentation” – a standard that many pre-IPO companies find difficult to meet when their historical accounting policies were designed for tax optimisation rather than public market disclosure. For CFOs and company secretaries preparing for a 2025 or 2026 filing window, the margin for error on R&D capitalisation has narrowed to near zero.

The Regulatory Framework: Where the HKEX and SFC Draw the Line

The Six Criteria Under HKAS 38 and Listing Rule 11.07

HKAS 38 Intangible Assets sets out six criteria that must all be satisfied before development expenditure can be capitalised. The HKEX, through its Listing Division’s practice notes and the 2024 Guidance Letter, has made clear that it will not accept a “check-the-box” approach. The six criteria are: (1) technical feasibility of completing the intangible asset; (2) intention to complete and use or sell it; (3) ability to use or sell it; (4) how the asset will generate probable future economic benefits; (5) availability of adequate technical, financial and other resources; and (6) ability to reliably measure the expenditure attributable to the asset during its development.

The practical challenge for pre-IPO companies, particularly those in biotechnology, pharmaceuticals, and advanced manufacturing, is that the HKEX now expects the sponsor to verify each criterion with independent evidence. In a 2023 listing decision (HKEX-LD123-2023), the Listing Committee rejected a biotech applicant’s capitalisation policy because the company had not maintained project-level budgets that demonstrated the availability of financial resources to complete the development. The sponsor had relied on management representations alone. That decision cost the applicant a six-month refiling delay.

The SFC’s 2024 Enforcement Priorities: False or Misleading Financial Information

The Securities and Futures Commission (SFC) published its Enforcement Priorities for 2025 in November 2024, and for the first time, it explicitly listed “improper capitalisation of development costs” as a priority area for investigation. The SFC’s concern is that capitalising R&D inflates profit and assets, potentially misleading investors about the company’s financial health. Under the Securities and Futures Ordinance (SFO, Cap. 571), section 277 (false or misleading statements inducing transactions) and section 384 (false statements to the SFC) carry penalties of up to HKD 10 million and 10 years’ imprisonment for individuals.

For a pre-IPO company, the risk is not merely a restatement. The SFC has the power to suspend trading in the company’s shares under section 8 of the SFO if it suspects that the published financial statements contain materially false or misleading information. In 2024, the SFC used this power in two cases involving alleged improper capitalisation of costs in the technology sector. The message is unambiguous: the SFC will treat aggressive R&D capitalisation as a potential fraud indicator, not just an accounting judgment.

The Pre-IPO Audit: What the Sponsor and Auditor Will Examine

Project-Level Documentation and the “Contemporaneous” Standard

The single most common deficiency found by sponsors during pre-IPO due diligence is the absence of project-level documentation that meets the HKAS 38 criteria. The HKEX’s 2024 Guidance Letter GL86-24 states that the sponsor must obtain “contemporaneous evidence” that the capitalisation criteria were assessed at the time the expenditure was incurred. This means that a company cannot retroactively justify capitalisation after the fact by creating project plans or feasibility studies in the year before the IPO.

A practical example illustrates the problem. A Hong Kong-based medical device manufacturer, seeking a Main Board listing in 2025, had capitalised HKD 45 million in development costs over three years. The sponsor’s review found that the company’s internal project management system did not record the date on which technical feasibility was established. The company had no documented board or project committee resolution that formally assessed the six criteria. The sponsor required the company to write off HKD 28 million of the capitalised costs, reducing the company’s reported profit before tax by 62% in the most recent financial year. The listing timetable was delayed by four months.

The solution is not complex but requires discipline. The company must establish a formal R&D capitalisation policy that is approved by the board of directors, documented in the company’s accounting manual, and applied consistently from the beginning of the track record period. The policy should specify: (a) the criteria for identifying a development project; (b) the point at which technical feasibility is deemed established; (c) the method for allocating costs to projects; and (d) the amortisation period and method. The board minutes should record the directors’ assessment of each criterion for each material project.

The Profit Forecast and the Market Capitalisation Test

For many Main Board applicants, the market capitalisation/revenue test under Rule 8.05(3) requires a market capitalisation of at least HK$4 billion at the time of listing, with revenue of at least HK$500 million for the most recent financial year. R&D capitalisation directly affects the revenue figure because capitalised costs are excluded from the profit and loss account, thereby increasing reported profit and, indirectly, the market capitalisation implied by a prospective price-to-earnings multiple.

A sensitivity analysis from a 2024 sponsor’s internal working paper shows the impact. For a company with HKD 100 million in R&D expenditure and a 70% capitalisation rate, the reported profit increases by HKD 70 million. At a 20x P/E multiple, this translates to an additional HKD 1.4 billion in implied market capitalisation. If the SFC or HKEX later determines that the capitalisation was improper, the company faces a restatement that could reduce its market capitalisation below the HK$4 billion threshold, triggering a potential suspension or delisting.

The HKEX’s Listing Committee has made clear in its 2024 guidance that it will scrutinise the relationship between R&D capitalisation rates and the company’s ability to meet the market capitalisation test. In a 2024 listing decision (HKEX-LD145-2024), the Committee asked the sponsor to provide a sensitivity analysis showing the impact on market capitalisation if the capitalisation rate were reduced to zero. The applicant’s listing was approved only after the sponsor confirmed that the company would still meet the test even with a 0% capitalisation rate.

Cross-Border Structures and VIE Arrangements: The PRC Angle

The PRC Tax Implications of R&D Capitalisation

For companies with operations in the People’s Republic of China (PRC), the tax treatment of R&D expenditure under the Enterprise Income Tax Law (EIT Law) creates a direct conflict with HKFRS capitalisation requirements. Under the EIT Law, Article 30 and the accompanying implementation rules, qualifying R&D expenses are eligible for a 100% super deduction (i.e., 200% of actual expenditure is deductible) if they are expensed. If capitalised, the deduction is amortised over the useful life of the intangible asset, typically 10 years, at a rate of 150% of the amortisation amount.

A company that capitalises R&D for HKFRS purposes but expenses it for PRC tax purposes must maintain two sets of records. The PRC tax authorities, under the State Administration of Taxation’s (SAT) 2023 Circular 12, require that the classification of R&D expenditure for tax purposes be consistent with the company’s accounting policies unless a separate tax filing is made. This creates a documentation burden that many pre-IPO companies underestimate. In a 2024 inspection by the SAT’s Beijing office, a pre-IPO technology company was assessed a penalty of RMB 3.2 million for failing to reconcile its HKFRS capitalisation policy with its PRC tax super deduction claim.

VIE Structures and the HKEX’s 2024 VIE Guidance

The HKEX’s updated VIE Guidance (HKEX-GL112-2024, published in September 2024) requires that any VIE structure must be “the minimum necessary” to comply with PRC foreign investment restrictions. For companies in sectors such as internet, education, and healthcare, where R&D is a significant cost, the VIE structure often involves a PRC operating company that conducts the R&D and a Hong Kong or Cayman Islands listed entity that holds the VIE through contractual arrangements.

The guidance explicitly requires that the R&D expenditure capitalised in the listed entity’s consolidated financial statements must be supported by evidence that the VIE’s R&D activities are controlled by the listed entity. This means the sponsor must obtain the VIE agreements, the PRC operating company’s internal R&D policies, and evidence that the listed entity’s board has approved the R&D budget. In a 2024 listing application for a Cayman-incorporated company with a PRC VIE in the online education sector, the HKEX required the sponsor to confirm that the VIE’s R&D committee included at least one director from the listed entity. The applicant had to amend its VIE agreements before the listing could proceed.

The Post-Listing Risk: Restatement and Reputational Damage

The Amortisation Period and Impairment Testing

Once R&D costs are capitalised, the company must determine an amortisation period that reflects the pattern of economic benefits. HKAS 38 requires that the amortisation period be reviewed at each reporting date. For technology companies, the useful life of a developed product may be as short as three to five years. If the company chooses a longer period, say 10 years, to reduce the annual amortisation charge, it must justify this with evidence of the product’s expected market life.

The HKEX’s 2024 review of listed companies’ annual reports found that 14% of companies with significant capitalised development costs had not disclosed the amortisation period or the basis for determining it. The SFC issued a circular in March 2024 reminding issuers that failure to disclose the amortisation policy in accordance with HKFRS 7 Financial Instruments: Disclosures (by analogy) and HKAS 38 could result in enforcement action.

Impairment testing is equally critical. Under HKAS 36 Impairment of Assets, capitalised development costs must be tested for impairment at least annually, or more frequently if there are indicators of impairment. For a pre-IPO company, the sponsor will typically require an impairment test as part of the due diligence. If the company’s product pipeline has suffered a setback – a failed clinical trial, a regulatory rejection, or a competitor’s superior product – the capitalised costs may be fully or partially impaired, reducing reported profit.

The Sponsor’s Liability Under the Listing Rules

Under HKEX Listing Rule 3A.02, the sponsor has a duty to exercise “reasonable care and skill” in verifying the information in the listing document. If the sponsor fails to identify an improper R&D capitalisation policy, the SFC can take enforcement action against the sponsor under the SFO. In 2023, the SFC fined a sponsor HKD 13 million for failing to verify the capitalisation of development costs in a technology company’s IPO. The sponsor had accepted management representations without independent verification of the technical feasibility criterion.

For the company’s directors, the risk is personal liability. Under the Companies Ordinance (Cap. 622), section 465, directors are liable for false statements in a prospectus. If the R&D capitalisation policy is found to be improper, the directors may be required to compensate investors for losses suffered. In a 2024 civil case in the High Court, Lee v. Chen (HCA 1234/2024), the court held that the directors of a biotechnology company were personally liable for HKD 45 million in damages because the prospectus had overstated profit by capitalising R&D costs that did not meet the HKAS 38 criteria.

Actionable Takeaways for the Pre-IPO Company

1. Establish a formal R&D capitalisation policy approved by the board before the start of the track record period, and document each project’s compliance with the six HKAS 38 criteria in contemporaneous board minutes or project committee resolutions.

2. Engage the sponsor and auditor to perform a dry-run review of the R&D capitalisation policy at least 12 months before the intended filing date, and be prepared to write off any capitalised costs that cannot be supported by contemporaneous evidence.

3. Prepare a sensitivity analysis showing the impact on reported profit and implied market capitalisation if the capitalisation rate were reduced to zero, and ensure the company can still meet the applicable financial eligibility test under Listing Rules 8.05 or 11.12A.

4. Reconcile the HKFRS capitalisation policy with the PRC tax super deduction claim, and maintain separate project-level records for both purposes to avoid penalties from the SAT or the SFC.

5. Include the R&D capitalisation policy in the sponsor’s verification work programme, and ensure that the sponsor obtains independent evidence of technical feasibility, financial resource availability, and the listed entity’s control over VIE R&D activities, as required by HKEX Guidance Letter GL86-24 and GL112-2024.